Literature DB >> 3017332

Pharmacological profiles of a potential LTB4-antagonist, SM-9064.

M Namiki, Y Igarashi, K Sakamoto, T Nakamura, Y Koga.   

Abstract

Antagonistic activity against leukotriene B4 (LTB4) and other pharmacological activities of SM-9064 were studied in vitro and in vivo. It inhibited the chemotaxis of rat polymorphonuclear leukocytes (PMNLs) induced by LTB4 (IC50 = 1.3 X 10(-7) M, not by other chemoattractants. Its agonistic activity was much less than that of LTB4. It suppressed the Arthus reaction-induced inflammation in mice with the dose of 5 mg/kg, i.p. or 10 mg/kg, p.o. These results suggest that SM-9064 is a candidate of LTB4 antagonists, which is effective in some type of inflammation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017332     DOI: 10.1016/s0006-291x(86)80530-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Pharmacological profile of a novel, orally active leukotriene B4 antagonist, SM-15178.

Authors:  N Ohmi; C Tani; K Yamada; M Fukui
Journal:  Inflammation       Date:  1994-04       Impact factor: 4.092

Review 2.  Regulation of leukotriene biosynthesis.

Authors:  A W Ford-Hutchinson
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

3.  Role of oxygen radicals and arachidonic acid metabolites in the reverse passive Arthus reaction and carrageenin paw oedema in the rat.

Authors:  N K Boughton-Smith; A M Deakin; R L Follenfant; B J Whittle; L G Garland
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.